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Introduction
This paper presents a novel extension of a non-linear drug kinetic model, by Evans et al. [1] , on the in vitro uptake of the anti-cancer agent topotecan (TPT) for live human breast cancer cells (MCF-7 cell line) in order to account for cell transporters and drug resistance proteins. In this paper, the transporter located in the cell membrane acts as an efflux pump to drive the drug out of the cell before it can reach the target in the nucleus. The model permits analysis of the kinetics and temporal interactions of the pharmacologically active form of the drug to the DNA target. The scanning-laser microscopy experiment used to collect the data imposes an output structure on the model that corresponds to the functions of the variables that can be directly observed or measured (in this case, total concentrations of TPT in extracellular medium, cytoplasm and nucleus).
This paper consists of five main sections, including the introduction (Section 1), Section 2 provides a background on the underlying biochemistry of the anti-cancer agent TPT in addition to an introduction to drug efflux pumping mechanism and resistance proteins. Section 3 includes a detailed explanation of the mathematical model developed and a reduced order model generated via quasi-steady state assumptions that also yields a reduction in the number of the unknown model parameters.
The symbolic software MATHEMATICA [2] was used in this study to perform a structural identifiability analysis of the model (Section 4). Finally, experimental data collected have been used for parameter estimation (Section 5) using the software package FACSIMILE (MCPA Software, U.K.), further results and concluding remarks are outlined in this section.
Background

Action of the anti-cancer agent TPT
TPT is a derivative of Camptothecin (CPT), an extract from the Chinese tree Camptotheca acuminata and is water-soluble [3] [4] [5] . CPT is specific in that it acts as a reversible poison of the DNA cellular enzyme topoisomerase I [6] . TPT has been widely used against ovarian and small cell lung carcinomas [1] . The function of topoisomerase I enzyme is to facilitate DNA supercoiling by cleavage and religation of one strand of double-stranded DNA (dsDNA) [7] . Topoisomerase I is targeted by TPT in the nucleus, and traps it in a reversible ternary complex with DNA. The death of TPT-targeted cells results from the collision between the complex and the DNA replication process causing the dsDNA to break resulting in cell death [4, 6] .
The ring-closed, parent lactone form (TPT-L) undergoes reversible hydrolysis to an open-ringed hydroxy acid form (TPT-H). TPT-L is the pharmacologically active form in that it is the form of TPT which is responsible for inhibiting the enzyme topoisomerase I reversibly and maintaining the TPTtopoisomerase I-DNA complex as well as DNA binding. The reversible hydrolysis process is pH dependent, in which the parent form predominates at a high-acidic medium pH (<4), whereas the hydroxy acid form prevails in a high-basic medium pH (>10) [8] [9] .
The reversible hydrolysis of TPT-L was modelled by Evans et al. [10] using a linear two-compartment model with parameter estimation from high performance liquid chromatography (HPLC) data in buffers at different pH levels. A non-linear five-compartment model describing the uptake kinetics of TPT in a medium enclosing human lymphoma cells (SU-DHL-4 cell line) was developed based on the two-compartment model. The non-linear model characterises the kinetics of TPT in the entire cell population [1] . Similar to the model in Evans et al. [10] , the unknown parameters for the fivecompartment model were estimated from HPLC data.
TPT is a naturally fluorescent agent which can be excited using ultra-violet wavelengths (350-360 nm) and detected at a visible wavelength with peak emission at 540 nm. Accordingly, HPLC is used to compute the amount of drug in human plasma [10] and extracts. The binding characteristics of drug to DNA have been determined using the high-photon absorption property [8] . In the current paper, delivery and localisation of the drug in single cells are examined using two-photon laser scanning microscopy. The optical sectioning capacity of this technique provides high-resolution spatial information representing the fluorescence intensity in the compartments and, therefore, quantifying the drug concentration in these compartments, i.e. nucleus, cytoplasm and extra-cellular environment. The kinetics of the uptake for each sub-compartment can be analysed via time-lapse sequences, thus providing the primary data for mathematical modelling, and parameter estimation.
The BCRP/ABCG2 drug efflux pump and the enzyme ALDH
One of the major forms of cancer treatment is chemotherapy. In general, cancers are either resistant to chemotherapy or obtain resistance during treatment, thereby leading to ineffective chemotherapy [11] .
Examples of drugs to which resistance has been observed or acquire resistance during treatment include topoisomerase inhibitors (eg, TPT), anthracyclines (eg, doxorubicin), the Vinca alkaloids (eg, vincristine) and the taxanes (eg, paclitaxel) [11] . The model in this paper describes the mechanism by which human cancers develop resistance to drugs, that is, the overexpression of efflux transport proteins in the plasma membrane of cancer cells. Examples include, P-glycoprotein (P-gp) [12] in addition to the multidrug resistance protein 1 (MRP1) [13] . More recently, other human binding cassette (ABC) transporters that are involved in the resistance of anti-cancer drugs have been discovered. The most important of these is the breast cancer resistance protein (BCRP) also known as ABCG2 [14] , placenta specific ABC protein [15] or mitoxantrone-resistance protein [16] .
Studies conducted in various laboratories have verified that enforced expression of BCRP complementary DNA in different types of cells caused resistance to multiple anti-cancer drugs including TPT and reduced drug accumulation in the cell [17] [18] [19] . This protein is significantly expressed in organs central for absorption, distribution, elimination, and deposition of drugs. Further investigations have come to the conclusion that BCRP plays a significant role in drug deposition [11] .
BCRP, also known as ABCG2, is the second member of the sub-family G of the human ATP binding cassette (ABC) transporter. Moreover, BCRP is a half-transporter, in that it consists of a one nucleotide binding domain followed by a one membrane-spanning domain, which is unlike P-gp and MRP1 which are arranged in two repeated halves. It has been shown from various studies on drug efflux mechanisms that BCRP is mostly localised at the plasma membrane instead of at internal vesicular membranes. Therefore, BCRP is presumably in active transport from the cell rather than in transport into internal vesicles [14, [20] [21] . The actual efflux pumping mechanism is explained in detail in the following section.
Aldehyde dehydrogenases (ALDHs) [aldehyde: NAD(P)
+ oxidoreductase] are an enzyme group that catalyse the conversion of aldehydes to the corresponding acids irreversibly by means of an NAD(P) + -dependent reaction [22] . ALDHs are distinguished based on properties including physicochemical characteristics, enzymological, subcellular localisation and tissue distribution [23] . ALDH enzymes demonstrate high activity in oxidising aldophosphamide and detoxifying anti-cancer agents. It has been proven that this drug resistance was associated with the transcriptional activation of ALDH expression in cancer cells [24] .
Mathematical model
Extended model
The original model proposed by Evans et al. [1] allows for mixing in the medium by dividing the medium into two separate pools: the medium region into which the drug is added and the extracellular region in which the cells are located. The drug exchange between the cells and medium takes place only through the extracellular region. In this model, the cellular pool that contains all of the individual cells has been extended to include the cell membrane. Therefore, this leads to a model with five experimental regions: the medium, the extracellular region, the cell membrane, the cytoplasm, and the nucleus which are denoted by subscripts m, e, cm, c, and n, respectively. and TPT-H in the extracellular region (H e ). In Evans et al. [1, 10] , it is assumed that all drug in the nucleus is bound and only TPT-L binds to DNA. This assumption is a simplification of the real case in which the nucleus may contain unbound drug as well; therefore, this postulation requires further experimental investigation. In the three experimental pools, i.e. medium, extracellular region and cytoplasm, TPT undergoes reversible and pH dependent hydrolysis. Assuming homogeneity in pH and/or any other factors that might have an effect on the hydrolysis, the rate constants are k cm and k om for the ring closing of TPT-H and ring opening of TPT-L, respectively, for both the medium and the extracellular region. Additionally, the corresponding rate constants for the cytoplasm are k cc and k oc .
ALDH isozymes including ALDH1A1, are important for multiple biological activities including drug resistance [25] [26] . We have demonstrated that the uptake of TPT in cells exposed to an ALDH inhibitor (disulfiram) is enhanced (unpublished; data not shown). Moreover, kinetic analysis of TPT uptake also suggests that the change in charge upon ring hydrolysis would favour exclusion via the ABCG2 pump, and this is the overriding process to remove TPT from the cellular environment [27] .
Therefore based on these analyses, the active drug in the cytoplasm is assumed to bind irreversibly to the enzyme ALDH where it is converted to the form favoured by the efflux pump (TPT-H). The rate at which TPT-L binds to ALDH is assumed to be proportional, with the association rate k a , to the product of the concentrations of TPT-L in the cytoplasm, L c (t), and free enzyme, E(t). Additionally, dissociation of drug bound to ALDH occurs at a first-order rate, with rate constant k d . If E 0 denotes the total concentration of available ALDH, then the concentration of free ALDH is
where EL c (t) is the concentration of enzyme-drug complex. In the nucleus, it is assumed that only TPT-L binds to DNA and that all drug is bound.
( Fig. 1 here) Mixing between the medium and extracellular pools can be modelled by first-order flows between them. Assuming that the rate constants are the same for the lactone and hydroxy acid forms, k mi denotes the flow from the medium to the extracellular pool and k mo denotes the flow out of the extracellular pool to the medium.
Flow between the extracellular region and the cellular pool, including the cell membrane and cytoplasm, takes place simultaneously via two distinct processes. The first process is the efflux pumping mechanism in which the BCRP/ABCG2 transporter carries TPT-H through the cell membrane to the extracellular region irreversibly. The rate at which TPT-H in the cytoplasm binds to the efflux pump is assumed to be proportional, with association rate constant k 1 , to the product of the concentrations of the inactive drug in the cytoplasm, H c (t), and free transporter, T(t). The dissociation of drug bound to the efflux pump (TH cm ) is assumed to be first order with rate constant k 2 
. Dissociation of bound drug is assumed to occur at a firstorder rate as either TPT-L, with rate constant k dl , or TPT-H, with rate constant k dh . Thus TPT-L may bind to DNA in a reversible manner and can then, once bound, be converted to TPT-H [28] .
If the volumes of the medium, extracellular region, cytoplasm, cell membrane and nucleus, are denoted by V m , V e , V c , V cm , and V n , respectively, then the postulated mathematical model for the uptake kinetics of TPT is given by the following system of differential equations:
() 
where D is the concentration of dose in the full physical medium (i.e. 2 ml or 2×10 12 μm 3 ).
According to Evans et al. [1, 10] , the estimates obtained for the volumes, using data collected from optical sectioning using a confocal microscope, are: 
In the experiment used to collect data for parameter estimation, concentrations were measured in μΜ, the initial dose was D = 10 μΜ, and time was measured in seconds.
Pseudo-steady state approximation of the model
In this section, the extended model in Fig. 1 is reduced by assuming that the binding kinetics of both the ALDH enzyme and the BCRP/ABCG2 efflux pump are saturable within the physical volume of space considered. That is the concentrations of the enzyme and the transporter are much lower than the concentration of associated substrates. A structural identifiability analysis (Section 4) of the unknown parameters of the system is performed for the reduced system following a pseudo-steady state approximation [30] . The structural identifiability properties of the reduced model will change from those of the original system [31] . Therefore, fewer system parameters (of the basic model) may be structurally globally identifiable as they enter in new parameter groupings in the reduced order model.
This technique is widely applied to models in pharmacokinetics, biology and biomedicine.
The assumptions on the relative sizes of the model parameters, are the following, firstly, the concentration of the enzyme is much lower than the active form of the drug in the cytoplasm, that is 
where respectively [32] .
Such (outer solution) approximations provide accurate results for the asymptotic behaviour of drug uptake. Moreover, the number of unknown parameters in the model has been reduced by two and the system equations are reduced to seven.
Identifiability analysis
Structural identifiability
Based on the microscopy experiments used to collect data for parameter estimation, an output structure on the suggested model has been imposed. This consists of functions of the model variables that are directly measured. The output structure has to uniquely determine the unknown parameters in the postulated model to obtain meaningful parameter estimates. If the unknown parameters are not uniquely determined, the proposed experiment should be redesigned (if possible) in order to obtain an output structure that uniquely determines the unknown parameters. Therefore, a structural identifiability analysis is a prerequisite for experiment design, system identification and parameter estimation. In mathematical terms, consider a postulated parametric model given by: 
The input in this particular experiment consists of a single impulse, i.e. injection of the drug TPT into the system, therefore, the corresponding amounts, are included in the initial conditions x 0 (p).
Otherwise, there are no external inputs to the system and no further input terms are included in (14) .
If a parameter can take any of a distinct (countable) number of values for a given observation function, y(t, p), then the parameter is locally identifiable [33] . In particular, if the parameter can only take a unique value (in the entire parameter space) for the given observation function, then the parameter is globally (uniquely) identifiable for that particular experiment. Otherwise, the parameter is unidentifiable.
Definition 1.
A compartmental system of the form (14) - (17) (14) - (17) is said to be unidentifiable if at least one of the unknown parameters (p i ) of the model is unidentifiable.
The Taylor series approach [34] is applicable to systems in which the administration is through bolus injection. This method depends upon expanding components of y(t, p), the observation function, as
Taylor series around t = 0
+ . An important condition to perform this test is that the observation must be analytic. For the system described in (14) - (17), the Taylor series approach is used to verify that the system is structurally globally identifiable. Uniqueness of the coefficients in the Taylor series 
Structural identifiability analysis of the system
For the structural identifiability analysis of this model, the Taylor series approach is applied to the pseudo-steady state model ( (1)- (3) and (7)- (13)) with initial conditions given in (10) . The vector p comprising the thirteen unknown parameters of the model is given by:
( , , , , , , , , , , , , ) . ( (1 ) ) .
Using (19) and applying the 2 nd derivative (k = 2) yields: 
Now considering the next derivative (k = 3) in addition to using the relations in (19) and (20) 
Calculating the fourth derivative terms (k = 4) and using the relations in (21), yields 
From the next set of coefficients in the Taylor series expansions (k = 5), as well as using the relations in (21) and (22), the following relations must hold in order to satisfy (18) for each i and k = 0, …, 5:   00   22   2  2   1  2  2  1  1  1  2  2  1  2  1  2  1  1  2  2  1  1  2  2  1  2  2 , , , 
Equating and substituting the parameter relations resulting from equating the sixth derivative (k = 6) in (23) gives   11  1  1   2  2  0  0  2  2   ,  ,  , 
Finally, equating the eighth set of coefficients (k = 7), and using the relations in (24) yields
Equation (18) is therefore satisfied, that is pp (for each i and all k). This is true for generic p , thus the model is structurally globally identifiable, that is all of the model parameters are uniquely determined by the output structure corresponding to the proposed experiments.
Parameter estimation
TPT uptake into each cellular compartment was screened using two photon laser scanning microscopy.
The set up of the instrument was calibrated in order that the fluorescence response was linear for 0-15 µM TPT, therefore, making the conversion to the concentration of drug from fluorescence intensity (following background subtraction) simple to calculate [1] .
Parameter estimation was performed using the commercial simulation software package FACSIMILE (MCPA Software, U.K.). This software uses a robust implicit numerical integrator. The optimisation method used to obtain parameter estimates involves the minimisation of the weighted least-squares criterion given by:
where y i (t j ) is the ith output of the model at the jth sampling time (t j ) and the corresponding experimental data point is denoted by d i (j). The dynamic fluorescent intensities representing the drug concentration were derived from the three main cell compartments: the nucleus, cytoplasm and medium. Experimental data points were collected starting from t 1 = 0 second to t 91 = 450 seconds.
Therefore, each cell has three observations at each sampling time t j . The standard error associated with the data series
is denoted by σ i [35] . The standard error (σ i ) in FACSIMILE is equal to the product of e (estimate of the overall accuracy of the data) and R i (range for the experimental data point), i.e., σ i = eR i .
The method that FACSIMILE uses in estimating parameters involves the natural logarithms of the model parameters. During the fitting procedure, a statistical analysis is performed to detect parameters that are not well-determined (NWD) by the data. Once detected, NWD parameters are treated as unknowns in subsequent tests. The default standard deviation of the natural logarithm (SDLN) of each of the remaining fitted parameters, P 0 , is estimated from the variance-covariance matrix of P -P 0 [1] . The 5%
and 95% confidence limits are estimated for each of the well-determined parameters, assuming a normal distribution for the natural logarithms of these parameters.
Three different types of curve fittings were conducted for the model represented in (1)- (13) at pH = 7.2. Firstly, data from 13 individual cells were averaged and the postulated model fitted to these averaged data, as shown in Fig. 2a . Secondly, the model was fitted to data from an individual high loading cell (relatively high concentration of L n (t)) (Fig. 2b) . Thirdly, data from an individual low loading cell (relatively low concentration of L n (t)) were used in the fitting (Fig. 2c) . The chosen value of pH was 7.2 for the three fittings, i.e., averaged data fitting, high loader and low loader. The fitted (estimated) parameter values with estimates for their confidences are presented in Tables 1-3 , where it is seen that all parameters are well-determined by the data. These parameter estimates correspond to the averaged data fitting, high loader fitting and low loader fitting respectively. The model fits in Fig. 2 show that there is close reproduction of the experimental data by the simulated output from the model with parameters taking values from Tables 1-3. ( Fig. 2 here) Based on Tables 1-3 , the estimated parameters are well-determined across the three fits. Additionally, the rate constant for the efflux of L c (t) into the extracellular pool (k e ) is lower in the high loader than the low loader, indicating that this parameter plays an important role in maintaining the drug in the nucleus. Moreover, the rate constants for the flow of both L e (t) and L m (t) into the cytoplasm and extracellular pool (respectively) are higher in the high loader suggesting that these parameters preserve the active form of drug in the cellular pool. However, the binding constant (k b ) at which TPT-L binds to DNA increases for the high loader, which offers another reason why the cells receive more pharmacologically active drug. The binding affinity of the drug (k m1 ) to the efflux pump is around 750 times higher in the low loading cells, therefore, the drug transporter mainly resists the anti-cancer agent TPT. The rate constant for dissociation of bound drug (k dl ) is relatively low for the high loading cell, providing another reason for the retention of the active form of the drug bound to DNA for these cells.
Although the concentration of TPT-L in the nucleus for the high loader is relatively high compared to that for the low loader, the value of B T in the low loading cell is approximately 35 times larger. This suggests that the efflux pumping mechanism plays a key role in the resistance of anti-cancer drugs.
( Table 1 here) ( Table 2 here) ( Table 3 here) Fig. 3 shows normal probability plots of the three fittings, i.e. average, high loader and low loader, and this is used to test whether or not the weighted residuals are normally distributed with standard deviation of 1 and zero mean. To obtain these normal probability plots [36] ; the residuals are listed in an ascending numerical order r 1 < r 2 < < r 273 (the smallest value is numbered 1 and the largest is numbered 273), and z i = (i -0.5 )/273 where (i = 1, …, 273). Next, data tables for the normal distribution are used to obtain a Z i value from the standard normal distribution corresponding to the cumulative probability given in the previous step. Finally, the resulting graph from the Z i values plotted against the ordered residuals (r i ) is the normal probability plot. Fig. 3 suggests that the residuals are normally distributed (with zero mean and a standard deviation of 1) since the graph is approximately linear. This is an indicator for the appropriateness of the standard error σ i used for each observation y i .
( Fig. 3 here) 
Conclusions
A compartmental model of the in vitro kinetics of the anti-cancer agent TPT has been extended from a previously published model. The postulated model takes into account the effect of ALDH enzyme and the elimination of drug from the cytoplasm via the efflux pump.
Structural identifiability, which is an a priori analysis for parameter estimation, was performed using the computer algebra system MATHEMATICA, this tool has proven useful for symbolic computations mainly when they become algebraically complicated. The identifiability analysis demonstrates that all of the unknown model parameters are uniquely determined by the output structure corresponding to the real experiment.
Parameter estimation was performed using the robust software package FACSIMILE. Three different curve fittings were conducted for average, low loading and high loading cells. Model simulations have been compared with live human breast cancer cell (MCF-7 cell line) data and found to give good qualitative agreement. All unknown model parameters were estimated to a high level of confidence. In comparison between the three curve fittings, the averaged data from the 13 individual cells, the high loading cell and the low loading cell, the efflux pumping mechanism resulting from BCRP/ABCG2
transporter is a key factor in resisting the anti-cancer agent TPT. According to the normal probability plots for the weighted residuals for each of the three curve fittings, it is suggested that the weighted residuals in the three cases are normally distributed with zero mean and standard deviation of 1 indicating the appropriateness of the constant standard errors used for each observation.
The model allows in silico estimations and predictions of the relationship between the target binding and the dose, with different expressions of the drug resistance protein and the ALDH enzyme, leading to the possibility of the design of optimal dosing regimens. The next step is to use the extended singlecell model in this paper to consider compartmental modelling for a population of cells and compare it to the multi-cell model described in Cheung et al. [37] , to determine sensitivity, model robustness and model validation. Moreover, the current kinetics model will be coupled with a dynamics model to study the response of the regulatory protein cyclin B with the presence of the anti-cancer agent TPT to assist in drug design. 
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